What is SNY's current stock price?

As of now, SNY is trading at $46.01, with a daily change of -2.17%.

What are the risks associated with SNY stock?

SNY has Low, risk level based on volatility, sector strength, volume, investor confidence and outlook.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

SNY Stock Analysis & IQ Rating | Sanofi

SNY

Sanofi

$46.01

-$1.02 | -2.17%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$60.12

MKT CAP

$112.09B

52W Low

$44.62

VOL

$8.98M

P/E Ratio

19.16

AVG VOL

$4.12M

RSI

40.78

TREND

Downtrend

SNY Stock IQ

Login to see Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

SNY Target Price

Login to display

Strengths

SNY Rewards

Earnings are forecast to grow

SNY Rewards

Trading below its fair value

SNY Rewards

Upgraded on attractively valued

SNY Rewards

Expands stock buyback program

Technical Indicators

SNY Technical Indicators

52-week Low

SNY Price Performance

$45.74 (+0.59%)

$49.55 (-7.14%)

$46.88 (-1.86%)

$57.7 (-20.26%)

1year

6month

3month

1month

SNY Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

SNY Analysts Opinion

SNY Analysts opinion is positive and also has improved from the past 3 months

SNY Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

87%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

67%

100%

SNY Street Sentiment

SNY Street Sentiment is extremely bullish and have positive views on the near-term outlook

SNY Risk Level

SNY has Low risk level

Risks Indicators

Investors losing confidence

Hit 52-week low

Low

LOW

HIGH

SNY Performance Sentiment

Sentiments overview associated with events and the stock performance

87%

11%

Positive

Negative

55 out of 63
events present

7 out of 63
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$46.01

Resistance
Price

$45.74

Current Price Range

$49.25

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

50%

Buy

Hold

Sell

Consensus Rating

NEUTRAL

3

2

1

Date

Action

Rating

Firm

Feb 12, 2026

Downgrade

Neutral

BofA

Jan 26, 2026

Downgrade

Neutral

UBS

Jan 12, 2026

Downgrade

Equal

Barclays

Dec 30, 2025

Reiterate

its Buy

Jefferies

Dec 16, 2025

Reiterate

Buy

INTESA SANPAOLO EQUITY RESEARCH

SNY Latest Analysis +

SNY Stock Falls After Board Suddenly Makes Leadership Change. Sanofi stock slides 4.5% after it decides not to renew CEO Paul Hudsons mandate and names Belen Garijo as successor amid investor skepticism.

Fri Feb 13, 2026

$46.01 | -2.17%

Activity

Momentum

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors. Sanofi SA (NASDAQ:SNY) shares are down during Fridays premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline.On Thursday the French drugmaker with a market cap of around $113.6 billion closed 4.5% lower closer to the lower end of the 52-week

Fri Feb 13, 2026

$46.01 | -2.17%

Technical

Sanofis new CEO needs to fix drug pipeline and navigate Trump.

Fri Feb 13, 2026

$46.01 | -2.17%

Activity

Analysis-Sanofis new CEO needs to fix drug pipeline and navigate Trump.

Fri Feb 13, 2026

$46.01 | -2.17%

Activity

Sanofi: CEO Leaves With Project Rejuvenation Unfinished But Stock Undervalued.

Thu Feb 12, 2026

$47.03 | -4.51%

Potential

Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head. Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi after the French vaccine specialist announced it would not renew existing CEO Paul Hudsons contract.The abrupt leadership change at Sanofi brings a close to a six-year tenure under Hudson. Sanofis board thanked him for

Thu Feb 12, 2026

$47.03 | -4.51%

Activity

Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson. Sanofi stock skidded Thursday after the pharma giant'.s board ousted Paul Hudson as CEO replacing him with Merck KGaA'.s Belen Garijo.The post Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson appeared first on Investor'.s Business Daily.

Thu Feb 12, 2026

$47.03 | -4.51%

Momentum

Sanofi replaces CEO Paul Hudson names Belén Garijo as successor.

Thu Feb 12, 2026

$47.03 | -4.51%

Activity

Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant. French drugmaker Sanofi ousted CEO Paul Hudson on Thursday appointed Belén Garijo the head of German drugmaker Merck KGaA as new chief executive.

Thu Feb 12, 2026

$47.03 | -4.51%

Activity

Sanofi Shares Fall After CEO Change.

Thu Feb 12, 2026

$47.03 | -4.51%

Momentum

Runners Also Watch

Close Price

Change

PFE

Pfizer

27.58

+0.42%

REGN

Regeneron Pharma

803.17

+2.49%

NVS

Novartis AG

163.10

+1.16%

MRK

Merck Company

121.41

+1.78%

ABBV

AbbVie

231.50

+1.76%

FAQ About SNY Stock Insights

What is SNY current stock price?

What are SNY stock strengths?

What is SNY Risk Level?

What is SNY market cap and volume?

What is SNY current Stock IQ?

Should I buy SNY stock right now?

Is SNY a Strong Buy right now?

What does a 'Strong Buy' rating mean for SNY?

What does a 'Strong Sell' rating mean for SNY?

What factors influence SNY's Stock IQ?

Explore our SNY Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored SNY Stock Strategies
Effective Risk Management

FIND US ON

Receive our SNY Daily Alerts

Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

SNY

Sanofi

Set Alerts

Current Price

$46.01

-$1.02 | -2.17%

52W High

$60.12

MKT CAP

$112.09B

52W Low

$44.62

VOL

$8.98M

P/E Ratio

19.16

AVG VOL

$4.12M

RSI

40.78

TREND

Downtrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Runners Also Watch

Symbol

Close

Change

PFE

Pfizer

27.58

+0.42%

REGN

Regeneron Pharma

803.17

+2.49%

NVS

Novartis AG

163.10

+1.16%

MRK

Merck Company

121.41

+1.78%

ABBV

AbbVie

231.50

+1.76%

SNY Price Performance

$45.74 (+0.59%)

$49.55 (-7.14%)

$46.88 (-1.86%)

$57.7 (-20.26%)

1year

6month

3month

1month

SNY Analysts Opinion

Overall standing per market and analyst expectations. menu Hover over the category for more information

SNY Analysts Opinion

SNY Analysts opinion is positive and also has improved from the past 3 months

SNY Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

87%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

67%

100%

SNY Street Sentiment

SNY Street Sentiment is extremely bullish and have positive views on the near-term outlook

SNY Risk Level

SNY has Low risk level

Risks Indicators

Investors losing confidence

Hit 52-week low

Low

LOW

HIGH

SNY Performance Sentiment

Sentiments overview associated with events and the stock performance.

87%

11%

Positive

Negative

55 out of 63
events present

7 out of 63
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$46.01

Resistance
Price

$45.74

Current Price Range

$49.25

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

50%

Buy

Hold

Sell

Consensus Rating

NEUTRAL

3

2

1

Date

Action

Rating

Firm

Feb 12, 2026

Downgrade

Neutral

BofA

Jan 26, 2026

Downgrade

Neutral

UBS

Jan 12, 2026

Downgrade

Equal

Barclays

Dec 30, 2025

Reiterate

its Buy

Jefferies

Dec 16, 2025

Reiterate

Buy

INTESA SANPAOLO EQUITY RESEARCH

Dec 16, 2025

Reiterate

Buy

Jefferies

Dec 16, 2025

Reiterate

Buy

ODDO BHF

Dec 16, 2025

Reiterate

Sell

DAY BY DAY

SNY Stock IQ

Login to unlock Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

SNY Rewards

Earnings are forecast to grow

SNY Rewards

Trading below its fair value

SNY Rewards

Upgraded on attractively valued

SNY Rewards

Expands stock buyback program

Technical Indicators

SNY Technical Indicators

52-week Low

SNY Latest Analysis

SNY Stock Falls After Board Suddenly Makes Leadership Change. Sanofi stock slides 4.5% after it decides not to renew CEO Paul Hudsons mandate and names Belen Garijo as successor amid investor skepticism.

Fri Feb 13, 2026

$46.01 | -2.17%

Activity

Momentum

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors. Sanofi SA (NASDAQ:SNY) shares are down during Fridays premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline.On Thursday the French drugmaker with a market cap of around $113.6 billion closed 4.5% lower closer to the lower end of the 52-week

Fri Feb 13, 2026

$46.01 | -2.17%

Technical

Sanofis new CEO needs to fix drug pipeline and navigate Trump.

Fri Feb 13, 2026

$46.01 | -2.17%

Activity

Analysis-Sanofis new CEO needs to fix drug pipeline and navigate Trump.

Fri Feb 13, 2026

$46.01 | -2.17%

Activity

Sanofi: CEO Leaves With Project Rejuvenation Unfinished But Stock Undervalued.

Thu Feb 12, 2026

$47.03 | -4.51%

Potential

Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head. Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi after the French vaccine specialist announced it would not renew existing CEO Paul Hudsons contract.The abrupt leadership change at Sanofi brings a close to a six-year tenure under Hudson. Sanofis board thanked him for

Thu Feb 12, 2026

$47.03 | -4.51%

Activity

Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson. Sanofi stock skidded Thursday after the pharma giant'.s board ousted Paul Hudson as CEO replacing him with Merck KGaA'.s Belen Garijo.The post Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson appeared first on Investor'.s Business Daily.

Thu Feb 12, 2026

$47.03 | -4.51%

Momentum

Discover SNY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of SNY. We're here to help you make informed investment decisions today.

FIND US ON

Receive our SNY Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

SNY Stock trends

SNY Stock performance

SNY Stock analysis

SNY investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing SNY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing SNY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

SNY Stock Analysis & IQ Rating | Sanofi

SNY Stock IQ

SNY Target Price

SNY Analysts Opinion

SNY Street Sentiment

SNY Risk Level

SNY Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our SNY Stock insights

Receive our SNY Daily Alerts

SNY Street Sentiment

SNY Risk Level

Key Price Levels

Latest Analyst Actions

Discover SNY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of SNY. We're here to help you make informed investment decisions today.

Receive our SNY Daily Alerts

SNY Alerts